In yesterday’s Wall Street session, Geron Corp. (NASDAQ:GERN) shares traded at $2.17, up 0.46% from the previous session.
As of this writing, 6 analysts cover Geron Corp. (NASDAQ:GERN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $4.00, we find $5.00. Given the previous closing price of $2.16, this indicates a potential upside of 131.48 percent. GERN stock price is now -18.26% away from the 50-day moving average and -21.42% away from the 200-day moving average. The market capitalization of the company currently stands at $1.14B.
There are 0 analysts who have given it a hold rating, whereas 5 have given it a buy rating. Brokers who have rated the stock have averaged $4.83 as their price target over the next twelve months.
With the price target maintained at $4, Goldman recently Upgraded its rating from Neutral to Buy for Geron Corp. (NASDAQ: GERN).
In other news, O’Farrell Elizabeth G., Director bought 6,607 shares of the company’s stock on Aug 24. The stock was bought for $15,064 at an average price of $2.28. Upon completion of the transaction, the Director now directly owns 7,407 shares in the company, valued at $16073.19. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 24, Director O’Farrell Elizabeth G. bought 6,579 shares of the business’s stock. A total of $15,000 was incurred on buying the stock at an average price of $2.28. This leaves the insider owning 26,220 shares of the company worth $56897.4. Insiders disposed of 2,194,719 shares of company stock worth roughly $4.76 million over the past 1 year. A total of 15.72% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GERN stock. A new stake in Geron Corp. shares was purchased by MARSHALL WACE, LLP during the first quarter worth $21,289,000. ARMISTICE CAPITAL, LLC invested $9,765,000 in shares of GERN during the first quarter. In the first quarter, SEGALL BRYANT & HAMILL, LLC acquired a new stake in Geron Corp. valued at approximately $7,475,000. BOXER CAPITAL, LLC acquired a new stake in GERN for approximately $6,510,000. OPALEYE MANAGEMENT INC. purchased a new stake in GERN valued at around $5,100,000 in the second quarter. In total, there are 249 active investors with 50.62% ownership of the company’s stock.
Wednesday morning saw Geron Corp. (NASDAQ: GERN) opened at $2.1800. During the past 12 months, Geron Corp. has had a low of $1.95 and a high of $3.84. As of last week, the company has a debt-to-equity ratio of 0.19, a current ratio of 5.20, and a quick ratio of 5.20. The fifty day moving average price for GERN is $2.6338 and a two-hundred day moving average price translates $2.7610 for the stock.
The latest earnings results from Geron Corp. (NASDAQ: GERN) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.09, missing analysts’ expectations of -$0.08 by -0.01. This compares to -$0.07 EPS in the same period last year. The net profit margin was -38007.78% and return on equity was -77.66% for GERN. The company reported revenue of $29000.0 for the quarter, compared to $73000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -60.27 percent. For the current quarter, analysts expect GERN to generate $60k in revenue.
Geron Corp.(GERN) Company Profile
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
